Regenerative Medicine Intelligence
Editorial coverage of regenerative science, clinical adoption, and the market forces shaping modern medicine.
Find stories by topic, category, or indication.
The FDA's proposed rule aims to strengthen accountability mechanisms for foreign tobacco manufacturers, safeguarding public health, particularly among youth.
Choose the topics you care about and receive new editions as they are released.
Recent findings highlight the essential role of the protein TRF2 in maintaining the identity of muscle stem cells, crucial for muscle repair and regeneration. A deficiency of this protein leads to the conversion of muscle tissue into fat and scar tissue.
The FDA has approved bemotrizinol as a new active ingredient in sunscreens, a significant advance in sun protection options that impacts clinical practice and patient care.
The FDA has granted supplemental approval for Casgevy, a gene therapy aimed at treating young children with Sickle Cell Disease and transfusion-dependent β thalassemia, marking a significant advancement in pediatric hematology.
Discover how regenerative medicine can help improve skin health and appearance, offering hope for those seeking youthful, glowing skin.
Discover how regenerative medicine can enhance hair health and what it means for you.
The FDA has granted Emergency Use Authorization for generic Nitenpyram Tablets to combat New World screwworm infestations in dogs and cats. This measure highlights the urgency in addressing this veterinary health issue, impacting pet owners and veterinary professionals alike.
The FDA has expanded access to the life-saving opioid overdose treatment, naloxone, by approving the over-the-counter intranasal formulation, Rextovy. This change aims to combat rising opioid overdose rates.
The FDA's recent accelerated approval of Tzield for certain pediatric patients represents a significant advancement in the management of recently diagnosed Stage 3 Type 1 Diabetes.
The FDA has authorized the first OTC continuous glucose monitor, aimed specifically at children aged two and older, marking a significant step in diabetes management.
The FDA has approved the first generic version of Xofluza, a breakthrough single-dose influenza treatment, heralding potential shifts in treatment accessibility and affordability.
DeepHealth has received FDA 510(k) clearance for its AI-based tool designed to enhance breast ultrasound imaging, which is a significant advancement in diagnostic technology.